GSK plc (GSK)
| Market Cap | 102.24B +16.4% |
| Revenue (ttm) | 44.05B +5.0% |
| Net Income | 6.40B +40.8% |
| EPS | 3.14 +42.6% |
| Shares Out | 4.01B |
| PE Ratio | 16.24 |
| Forward PE | 10.48 |
| Dividend | $1.79 (3.51%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 4,698,307 |
| Open | 50.80 |
| Previous Close | 51.10 |
| Day's Range | 50.64 - 51.25 |
| 52-Week Range | 42.89 - 61.70 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 60.51 (+18.79%) |
| Earnings Date | Oct 28, 2026 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for GSK stock is "Buy." The 12-month stock price target is $60.51, which is an increase of 18.79% from the latest price.
News
GSK (GSK) Prepares to Report Q3 Earnings Amid Dividend Sustainability Focus
GSK (GSK) Prepares to Report Q3 Earnings Amid Dividend Sustainability Focus
GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update
GSK NYSE: GSK highlighted clinical data across its oncology pipeline at the European Society for Medical Oncology meeting, including updates for its B7-H3 antibody-drug conjugate ris-rez, B7-H4 ADC mo...
GSK plc Transcript: ESMO 2026 Investor Briefing
Ris-rez showed activity in SCLC and osteosarcoma, while mo-rez reported a 62% ORR and 11.1-month median PFS at its selected ovarian cancer dose. AZUR-1 showed a 76% combined cCR12/pCR rate, and zidesamtinib achieved a 94% ORR in TKI-naive ROS1-positive NSCLC.
GSK plc Slides: FY 2026
GSK plc has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 27, 2026.
GSK’s return to cancer starting to pay off, STAT reports
GSK (GSK) is seeing its return to oncology start to pay off, STAT’s Andrew Joseph reports. In the past week, a cancer drug picked up an approval for another tumor…
GSK (GSK) Expands Oncology Pipeline Amid Solid Dividend Fundamentals
GSK (GSK) Expands Oncology Pipeline Amid Solid Dividend Fundamentals
GSK Accelerates Cancer Drug Development Amid Strategic Acquisitions
GSK Accelerates Cancer Drug Development Amid Strategic Acquisitions
GSK to nearly double cancer drugs in trials, WSJ reports
GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, the Wall Street Journal reported on Tuesday, citing an interview with a scientist
GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
EXCLUSIVE: The U.K. drugmaker currently has five approved cancer medicines and a clinical-stage portfolio of about 15 assets.
GSK reports Ris-Rez trial in China met primary endpoint
GSK (GSK) plc licensor Hansoh Pharmaceutical Group Co. announced “positive” results from its ARTEMIS-011 study, a pivotal phase III trial in China evaluating risvutatug rezetecan, or Ris-Rez, in patie...
GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study
An experimental drug for a hard-to-treat bone cancer, being developed by Hansoh Pharmaceutical and GSK, helped patients live longer without the disease worsening, according to data presented by resea...
GSK Announces Positive Phase Ib Data for Mo-Rez with 62% Response Rate
BlackRock ETF Trust II - iShares Flexible Income Active ETF notes that GSK plc announced updated data from the global phase I BEHOLD-1 trial for mocertatug rezetecan, also known as Mo-Rez, an investig...
GSK presents updated data from phase I BEHOLD-1 trial for Mo-Rez
GSK (GSK) announced updated data from the global phase I BEHOLD-1 trial for mocertatug rezetecan, Mo-Rez, an investigational B7-H4-targeted antibody-drug conjugate, ADC. Results showed clinically mean...
GSK announces interim results from phase II AZUR-1 trial of Jemperli
GSK (GSK) announced positive interim results from the phase II AZUR-1 trial evaluating Jemperli monotherapy as a standalone treatment approach in adults with stage II and III microsatellite instabilit...
Ionis Pharmaceuticals Announces FDA Approval of HIBSAGO, Eligible for 10-12% Royalties
Ionis Pharmaceuticals, Inc. reported that its partner, GSK, announced that the U.S. Food and Drug Administration has approved HIBSAGO for the treatment of chronic hepatitis B virus infection in combin...
GSK’s ViiV announce real-world evidence from OPERA cohort using Cabenuva
ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Shionogi as a shareholder, announced evidence from the OPERA observational cohort spanning five years of real-world...
Ionis Pharmaceuticals partner GSK announces FDA approval of Hibsago
Ionis Pharmaceuticals (IONS) partner GSK (GSK) announced that the FDA has approved Hibsago for the treatment of chronic hepatitis B, or CHB, virus infection in combination with nucleoside analogue rev...
FDA Approves GSK's Hibsago For Chronic Hepatitis B In Adults Without Cirrhosis
(RTTNews) - GSK plc (GSK) announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) to treat chronic hepatitis B (CHB) virus infection in combination with nucleos(t)...
GSK (GSK) Gains FDA Approval for Hibsago, Enhancing Dividend Appeal
GSK (GSK) Gains FDA Approval for Hibsago, Enhancing Dividend Appeal
GSK’s Hibsago approved by FDA for treatment of CHB
GSK (GSK) “announced that the FDA has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B, CHB, virus infection in combination with nucleos(t)ide analogue reverse transcriptase in...
Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB)...
FDA Approves GSK's Hibsago, Boosting Prospects for Dividend Sustainability (GSK)
FDA Approves GSK's Hibsago, Boosting Prospects for Dividend Sustainability (GSK)
FDA Approves GSK's Hibsago Injection for Chronic Hepatitis B, Boosting Dividend Stock Appeal (GSK)
FDA Approves GSK's Hibsago Injection for Chronic Hepatitis B, Boosting Dividend Stock Appeal (GSK)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
The US FDA said on Tuesday it had approved British drugmaker GSK's hepatitis B drug Hibsago, allowing patients with the liver infection a way to keep the virus under control after stopping treatment...
GSK's Jemperli Becomes First Approved Immunotherapy For MSI-H/dMMR Locally Advanced Renal Cancer
(RTTNews) - GSK plc (GSK) announced that the U.S. FDA has approved Jemperli as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H) or mismatch rep...